Nrg-Gy006-A Randomized Phase II Trial Of Radiation Therapy And Cisplatin Alone Or In Combination With Intravenous Triapine In Women With Newly Diagnosed Bulky Stage Ib2, Stage II, IIIb, Or Iva Cancer Of The Uterine Cervix Or Stage II-Iva Vaginal
Posted Date: Jun 10, 2019
- Investigator: Thomas Herzog
- Specialties: Cancer, Oncology, Ovarian Cancer
- Type of Study: Drug
To evaluate the efficacy of the experimental regimen of triapine (3AP), cisplatin, and radiation to increase progression-free survival relative to the standard / control regimen of cisplatin and radiation in women with uterine cervix and vaginal cancer.
Criteria:
To Be Eligible: Must Have New, Untreated Squamous, Adenocarcinoma, Or Adenosquamous Carcinoma Of The Uterine, Cervix Or Vagina, Life Expenceny Greater Than 20 Weeks, 18 Years Of Age Or Older, Non-Pregnant, No Current Or Prior Invasive Malignancy Within 3 Years,
Keywords:
Ovarian Cancer, Uterine Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com